Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01
← catalyst calendarNCT06727565 · readout ≤ 12 d
Sponsored by Gilead Sciences (industry) · GILD — their whole pipeline →. With Arcus Biosciences, Inc..
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
100estimated
Sites
23
Countries
Australia, China, France +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-18 | actual | When the study began enrolling |
| Primary completion | Aug 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2024-12-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Head and Neck Squamous Cell Carcinoma
Interventions
- Drug: Domvanalimab
- Drug: Zimberelimab
- Drug: Paclitaxel
- Drug: Carboplatin
Primary outcomes
what the primary-completion date above is the date OFObjective response rate (ORR)
measured Up to 36 months
Progression-free survival (PFS)
measured Up to 36 months
Permalink · GILD's whole pipeline · Catalyst calendar · Every registered study · What changed